Protara Q2 Loss Widens to $21.7M; Cash Runway Extends into 2028 but Burn Accelerates
TARA sits 34% above its 52-week low of $2.97.
Summary
Protara Therapeutics reported a wider Q2 2026 net loss of $21.7M on higher R&D spending. Cash reserves of $161.9M are expected to fund operations into 2028, but the burn rate is rising. Key warrants expired unexercised, and executives adopted new stock sale plans.
Key Events · Earnings and Guidance · TARA
-
Q2 Net Loss Widens to $21.7M
Net loss increased 45% YoY to $21.7M, driven by a 57% jump in R&D expenses to $17.0M as clinical trials for TARA-002 and IV Choline Chloride advance.
-
Cash Reserves Decline to $161.9M
Unrestricted cash and marketable securities fell to $161.9M from $197.9M at year-end 2025. Management expects the runway to extend into 2028, but the quarterly burn rate is accelerating.
-
9.75M Warrants Expire Unexercised
April 2024 Common Warrants covering 9.75M shares expired on June 29, 2026, removing a potential $51M funding source at $5.25/share. Only 370,000 warrants were exercised in H1 2026.
-
Executives Adopt 10b5-1 Sale Plans
CEO Jesse Shefferman adopted a new 10b5-1 plan for up to 540,364 shares and Chief R&D Officer Jacqueline Zummo adopted a plan for 372,893 shares, with sales beginning in September 2026.
Analysis · TARA · Life Sciences
Protara's Q2 net loss grew 45% year-over-year to $21.7 million as R&D spending surged to support three clinical programs. Cash and equivalents fell to $161.9 million from $197.9 million at year-end, though management says the runway extends into 2028. The burn rate is accelerating just as the company enters a capital-intensive period with multiple pivotal trials. The expiration of 9.75 million warrants removes a potential $51 million funding source, while new 10b5-1 plans by the CEO and R&D chief signal planned insider selling. The company has not yet tapped its $100 million ATM, preserving that option but also leaving dilution risk on the table.
At the time of this filing, TARA was trading at $3.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $231M. The 52-week trading range was $2.97 to $7.82. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.